Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887509 | 0.95 | AOC3 (0.53) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4888128 | 0.90 | AOC3 (0.51) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4887312 | 0.85 | AOC3 (0.55) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4887632 | 0.85 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4890242 | 0.85 | AOC3 (0.52) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL5178740 | 0.83 | AOC3 (0.44) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4990368 | 0.82 | AOC3 (0.67) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4890548 | 0.82 | AOC3 (0.66) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL974214 | 0.82 | AOC3 (0.73) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL975257 | 0.82 | AOC3 (0.51) | AOC3SMN1; SMN2KMT2AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 163/4885SMN1; SMN2 2277/4885KMT2A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.